All In Biotech

Drug Trial Radar · NCT07776873

Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke

Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke - A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Trial(HOPE-MeVO)

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 616 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

616

Planned (sponsor's estimate)

Start

Oct 6, 2026

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
The First Affiliated Hospital of Anhui Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The HOPE-MeVO study aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke due to medium vessel occlusion presenting 4.5 to 24 hours after stroke onset or last known well. Eligible patients will be selected based on CT perfusion imaging and randomly assigned to receive rhPro-UK plus standard medical treatment or standard medical treatment alone. The primary objective is to determine whether rhPro-UK improves functional outcome at 90 days.

Conditions

  • Acute Ischemic Stroke

Interventions

  • Recombinant Human Prourokinase for Injection (rhPro-UK)Drug

    Recombinant human prourokinase (rhPro-UK) is administered intravenously at a total dose of 35 mg: 15 mg over 3 minutes, followed by 20 mg over 30 minutes. Antithrombotic therapy is withheld for 24 hours after thrombolysis, with peri-thrombolysis monitoring performed according to standard intravenous thrombolysis practice. Other acute ischemic stroke treatment and subsequent management are individualized according to the 2026 AHA/ASA guideline and the participant's clinical condition.

  • Standard medical treatment (SMT)Other

    Standard medical treatment consists of antiplatelet therapy selected by the investigator according to the participant's clinical condition. The regimen may consist of aspirin 100 mg/day plus clopidogrel 75 mg/day, aspirin 100 mg/day alone, or clopidogrel 75 mg/day alone. Other acute ischemic stroke treatment and subsequent management are individualized according to the 2026 AHA/ASA Guideline for the Early Management of Patients With Acute Ischemic Stroke and the participant's clinical condition.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With a Modified Rankin Scale Score of 0-1Time frame: 90 days after randomization (±7 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.